Using network pharmacology technology to explore the potential mechanism of ZTC in the treatment of cerebral infarction, the active ingredients of ZTC and potential targets for the treatment of cerebral infarction are screened out, and a “drug-component-target,” “Dot network,” “PPI action network,” and “drug core target network” are constructed, of which ALB, CCL2, AKT1, etc., are the key core targets. This evidence concerns the gene AKT1 and brain infarction.